Overview
| The course runs from 9 November 2026 to 30 June 2027. |
The global health challenge of ensuring drug safety while maintaining public confidence has become increasingly complex. Pharmaceutical companies must employ dedicated pharmacovigilance professionals. NGOs need confidence that the medicines they supply are both effective and safe. Health authorities must deliver high-quality care while managing costs. Regulatory bodies must weigh the benefits of drugs against concerns about potential harms.
This intensive, modular course addresses the growing demand for professionals trained in assessing drug safety and evaluating the risks and benefits of drug use. As an introductory-level course, it is designed to meet the needs of a wide range of individuals. The diverse backgrounds and expertise of our lecturers ensure a strong balance of theoretical insight and practical applications.